SION — Stock Film
STOCK FILMSCENE 1/11SION · $44.06
Stock Expert AI presents
SION
Sionna Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Sionna Therapeutics, Inc. A quick introduction.

On the stock market since 2025, it operates in the world of health and science. It has 59 employees. Now — the numbers.

on the stock market since 2025
59 employees
$2B market value
Revenue last year:
$0
The loss that same year:
$0
Sales don’t cover the costs; the gap drains from the cash pile every year.

The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.

THE SALES TREND
The sales picture, year by year.

Red columns mark years that ended in a loss.

$0
2022
$0
2023
$0
2024
$0
2025
In the vault right now:
$0
DEBT: $8.7M
At this pace, that money lasts about 3.1 years.

Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
46
weak

Clearly below the class average.

FINANCIAL STRENGTH
69
strong

The cash pile is strong; debt and other items pull the grade toward the middle.

VALUATION
53
average

The price isn’t cheap next to earnings — that’s why this grade sits in the middle.

GROWTH
26
very weak

Clearly below the class average.

PRICE MOMENTUM
79
strong

Clearly above the class average — a step short of the very top.

WORTH WATCHING

Growth: Sales growth trails the sector average.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 2 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

WEAK SPOTS
Thin profit on each sale3/10
Executives aren’t buying3/10
WORTH WATCHING

Profit per Sale: The profit kept from each sale is thin.

THE FIVE-YEAR JOURNEY
Trading below its recent peak.

The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.

1
THE BRIGHT SIDE · 1/2
Strong cash, light debt

There is $235.9M in the vault; even if every debt were paid off, $227.2M would remain.

2
THE BRIGHT SIDE · 2/2
Analysts’ target sits above today’s price

The average analyst price target is $52.5019% above today’s price.

1
THE RISKS · 1/3
Small sales, big loss

A loss of $75.3M against $0 in annual sales.

2
THE RISKS · 2/3
A wildly swinging price

This stock swings about 3 times as much as the market average. Big rallies — and big drops — can both happen fast.

3
THE RISKS · 3/3
Executives lean toward selling

Over the last 12 months, executives reported 151 sells against just 25 buys. Not an alarm bell by itself, but a number worth watching.

FINALE · THE GRADE
C
0 / 100 · MoonshotScore

On our five-subject report card, SION sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.

The takeaway: SION is a high-risk stock — not yet profitable, and its future rides on its product catching on.

Analysts’ average target sits above today’s price, yet the valuation grade (53/100) says the stock isn’t cheap.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Jul 24, 2026 · stockexpertai.com · Stock Film